Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 2/20 | 0.50 |
| ▸ | CTSK | P43235 | 7/20 | 0.49 |
| ▸ | CTSB | P07858 | 3/20 | 0.49 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.48 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.48 |
| ▸ | NPY4R | P50391 | 5/20 | 0.48 |
| ▸ | NPY1R | P25929 | 3/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.47 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.47 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.47 |
| ▸ | NPY2R | P49146 | 2/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL335148 | 0.88 | CAPN1 (0.52) | PSMB1CTSKCTSBCTSSCTSL | |
| SCHEMBL334368 | 0.87 | PSMB1 (0.53) | PSMB1CTSKCTSLCAPN1CAPN2 | |
| SCHEMBL334717 | 0.87 | PSMB1 (0.53) | PSMB1CTSKCTSLCAPN1CAPN2 | |
| SCHEMBL10027648 | 0.87 | CAPN1 (0.55) | PSMB1CTSKCTSBCTSSCTSL | |
| SCHEMBL10027649 | 0.86 | CAPN1 (0.56) | PSMB1CTSKCTSBCTSLCAPN1 | |
| SCHEMBL335508 | 0.86 | NPY4R (0.51) | PSMB1CTSKCTSLCAPN1CAPN2 | |
| SCHEMBL334649 | 0.86 | NPY4R (0.51) | PSMB1CTSKCTSLCAPN1CAPN2 | |
| SCHEMBL334603 | 0.86 | NPY4R (0.54) | PSMB1CAPN1CAPN2NPY4RNPY1R | |
| SCHEMBL334016 | 0.86 | PSMB1 (0.49) | PSMB1CTSKCTSBCTSSCTSL | |
| SCHEMBL334080 | 0.86 | NPY4R (0.54) | PSMB1CAPN1CAPN2NPY4RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097582-B2 | Peptide derivatives useful as antimicrobial agents and for treating wounds | NEOBIOTICS AB (SE) | 2012-01-17 | — | — | US | disclosed |
| US-8097582-B2 | Peptide derivatives useful as antimicrobial agents and for treating wounds | NEOBIOTICS AB (SE) | 2012-01-17 | — | — | US | disclosed |
| US-20090118198-A1 | NOVEL PEPTIDE DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS FOR TREATING WOUNDS | ZULA DIAGNOSTICS AB (SE) | 2009-05-07 | — | — | US | disclosed |
| US-20090118198-A1 | NOVEL PEPTIDE DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS FOR TREATING WOUNDS | ZULA DIAGNOSTICS AB (SE) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118198-A1 | NOVEL PEPTIDE DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS FOR TREATING WOUNDS | VIP, NGLY1, ARG1 | PSMB1 1943/4885CTSK 1298/4885CTSB 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.